title: Effects of everolimus on cytokines, oxidative stress, and renal histology in ischemia-reperfusion injury of the kidney.
abstract: BACKGROUND
  To evaluate the effects of everolimus on renal ischemia-reperfusion injury (IRI).
  
  
  METHODS
  Wistar albino rats were divided into control, ischemia-reperfusion (IR), and ischemia-reperfusion/everolimus (IR/eve) groups. Everolimus was administered for seven consecutive days to the IR/eve group prior to injury. IR and IR/eve groups underwent forty-five minutes ischemia followed by the application of reperfusion at 2 and 24 hours. Blood samples and kidneys were taken from all animals.
  
  
  RESULTS
  . Serum blood urea nitrogen and creatinine levels increased at two hours of reperfusion in the IR and IR/eve groups, and decreased at 24 hours of reperfusion in the IR group. In the IR/eve group, we detected significantly high interleukin-6 levels and low tumor necrosis factor-alpha and malondialdehyde levels at 24 hours. Myeloperoxidase levels increased at two hours of reperfusion in the IR/eve group, but decreased significantly at 24 hours. Everolimus did not improve renal tubular and interstitial injuries in renal IRI.
  
  
  CONCLUSIONS
  It has been demonstrated that pretreatment with everolimus has beneficial effects on cytokines and oxidative stress in renal IRI. However, these effects are insufficient for the correction of histopathological changes and restoration of normal kidney function.
authors.affiliation: Gazi University, Department of Internal Medicine, 06510, Besevler, Ankara, Turkey. elifsuyani@hotmail.com
authors.forename: Elif
authors.initials: E
authors.lastname: Suyani
authors.forename: Ulver Boztepe
authors.initials: UB
authors.lastname: Derici
authors.forename: Tolga
authors.initials: T
authors.lastname: Sahin
authors.forename: Ebru
authors.initials: E
authors.lastname: Ofluoglu
authors.forename: Hatice
authors.initials: H
authors.lastname: Pasaoglu
authors.forename: Ozlem
authors.initials: O
authors.lastname: Erdem
authors.forename: Gonca
authors.initials: G
authors.lastname: Barit
authors.forename: Kadriye Altok
authors.initials: KA
authors.lastname: Reis
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Erten
authors.forename: Turgay
authors.initials: T
authors.lastname: Arinsoy
authors.forename: Sukru
authors.initials: S
authors.lastname: Sindel
mesh_terms: D000818:Animals; D016207:Cytokines / Q000378:metabolism*; D000068338:Everolimus; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007674:Kidney Diseases / Q000473:pathology / Q000628:therapy*; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000473:pathology / Q000628:therapy*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D016207:Cytokines; D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus